Search Results for: FGFR2

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel MDM2 MDM2 proto-oncogene
  • AKT phosphorylates targets in the cytosol
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • Trafficking of AMPA receptors
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ub-specific processing proteases
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Zinc
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Choriocarcinoma
  • Osteosarcoma
  • Glioma
  • Penile cancer
  • Alveolar rhabdomyosarcoma
Novel ELK4 ETS transcription factor ELK4
  • Prostate cancer
Novel OAT ornithine aminotransferase
  • Glutamate and glutamine metabolism
  • Pyridoxal phosphate
  • Ornithine
  • Gabaculine
  • Canaline
  • Ornithinaemia
Novel MGMT O-6-methylguanine-DNA methyltransferase
  • MGMT-mediated DNA damage reversal
  • Cysteine
  • Zinc
  • S-Methylcysteine
  • S-Benzylcysteine
  • Dinitrochlorobenzene
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
Novel PLSCR1 phospholipid scramblase 1
Novel PLXNA1 plexin A1
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • Other semaphorin interactions
Novel PTPRE protein tyrosine phosphatase receptor type E
  • Alendronic acid
  • Tiludronic acid
Novel SEC23IP SEC23 interacting protein
  • COPII-mediated vesicle transport
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
FGF10 fibroblast growth factor 10
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • FGFR1b ligand binding and activation
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Regulation of gene expression in early pancreatic precursor cells
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Signaling by FGFR2 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Aplasia of lacrimal and salivary glands
  • Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
PTPN11 protein tyrosine phosphatase non-receptor type 11
  • Interleukin-6 signaling
  • PI3K Cascade
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • GPVI-mediated activation cascade
  • Prolactin receptor signaling
  • PIP3 activates AKT signaling
  • Spry regulation of FGF signaling
  • Signaling by SCF-KIT
  • GAB1 signalosome
  • Downstream signal transduction
  • PECAM1 interactions
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signaling by Leptin
  • Costimulation by the CD28 family
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • Signal regulatory protein family interactions
  • Netrin mediated repulsion signals
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Regulation of IFNG signaling
  • RET signaling
  • Interleukin-20 family signaling
  • MET activates PTPN11
  • Regulation of RUNX1 Expression and Activity
  • Interleukin-37 signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Interferon alpha/beta signaling
  • Regulation of IFNA signaling
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • FLT3 Signaling
  • STAT5 Activation
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Dodecyltrimethylammonium
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Metachondromatosis
ANOS1 anosmin 1
  • FGFR1c ligand binding and activation
  • Negative regulation of FGFR1 signaling
  • Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
APP amyloid beta precursor protein
  • Platelet degranulation
  • ECM proteoglycans
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Lysosome Vesicle Biogenesis
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • The NLRP3 inflammasome
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Post-translational protein phosphorylation
  • TRAF6 mediated NF-kB activation
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Purinergic signaling in leishmaniasis infection
  • Amyloid fiber formation
  • Deferoxamine
  • Aluminium
  • Zinc
  • L-methionine (R)-S-oxide
  • Resveratrol
  • Tromethamine
  • Phenserine
  • Tetrathiomolybdate
  • CAD106
  • Mito-4509
  • Edonerpic
  • Dimercaprol
  • Copper
  • Florbetaben (18F)
  • Florbetapir (18F)
  • Flutemetamol (18F)
  • Zinc acetate
  • Aluminium phosphate
  • Aluminum acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Alzheimer's disease (AD)
FBXO7 F-box protein 7
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Parkinson's disease (PD)
FGF23 fibroblast growth factor 23
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR1c and Klotho ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 point mutants in cancer
  • Post-translational protein phosphorylation
  • Hypophosphatemic rickets; X-Linked dominant hypophosphatemia (XLH); Autosomal dominant hypophosphatemic rickets (ADHR); Autosomal recessive hypophosphatemic rickets (ARHR); Hereditary hypophophatemic rickets with hypercalciuria (HHRH)
FGF3 fibroblast growth factor 3
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • FGFR1b ligand binding and activation
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Signaling by FGFR2 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Kaposi's sarcoma
FGF8 fibroblast growth factor 8
  • Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
NECTIN1 nectin cell adhesion molecule 1
  • Adherens junctions interactions
  • Nectin/Necl trans heterodimerization
  • Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
BEX1 brain expressed X-linked 1
BEX2 brain expressed X-linked 2

Page 1 out of 3 pages